Sign in to view content

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Caroline Baumal, MD, FASRS

Video
Published 2021

Related

Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Eric Nudleman, MD, PhD
Annual Meeting Talks
2023
Randomized Trial of Initiating Therapy With Aflibercept, Laser, or Observation for Eyes With Good Vision and Center-Involved Diabetic Macular Edema
Carl W. Baker, MD, FASRS
Updates from the Field
2019
Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more